Group 1 Automotive reports Q1 2026 results on April 30, entering the print with a quietly improving set-up: shorts have been cutting exposure, options traders have turned calmer, and JPMorgan lifted its target just last week.
The most notable shift in positioning is the sharp drop in short interest. Bearish exposure fell almost 5% over the past week to 7.8% of the free float — roughly 965,000 shares — after holding above 1 million shares through most of April. The move lower was concentrated in a single session around April 22-23, when shorts trimmed by nearly 50,000 shares in two days. That 5-week high of around 1.06 million shares is now clearly behind the stock. Borrow costs have drifted higher — up roughly 24% over the week to 0.52% APR — but that remains a negligible rate in absolute terms. Availability has eased as the short position contracted, and at current levels there is no sign of meaningful squeeze pressure. The ORTEX short score of 52.3, down from 53.6 earlier in the month, reflects the same direction: the short-side setup is loosening, not tightening.
Options tell a more bullish story than the recent past. The put/call ratio dropped sharply to 0.87 on April 29, about one standard deviation below its 20-day average of 0.95. For most of April the PCR had been running well above 1.0 — between 1.04 and 1.06 — signalling elevated demand for downside protection. That overhang has cleared ahead of the print, with call activity now dominant. The 52-week range on the PCR runs from 0.54 to 2.04, so the current reading is closer to the bullish end of the annual spectrum. The combination of shorts reducing exposure and options traders dropping their hedges is an unusual alignment into an earnings event where consensus expects a decline.
The Street is broadly constructive but has tempered its enthusiasm on price targets. JPMorgan's Rajat Gupta raised his target to $385 on April 17, the most recent action, maintaining Overweight. Citigroup cut from $490 to $420 in early April while keeping Buy. Barclays trimmed from $470 to $455, also keeping Overweight. The mean target across the Street sits at $430 — about 23% above the current price of $349. The bull case centres on the Inchcape UK acquisition adding roughly $2.7 billion in annual revenues, a 12% lift in aftersales, and 300 basis points of operating leverage from restructuring. Bears counter with projected AEBITDA falling 5% to $990 million and adjusted EPS declining 11% to $39.21, with EBITDA margins compressing to 4.6%. The EV/EBITDA multiple of 9.8x and a P/E of 8.0x are both modest, and a forward EPS growth score in the 71st percentile suggests the Street does see earnings recovering — even if near-term estimates are coming down.
Earnings history adds context without offering comfort. The last print on April 22 produced a 1-day drop of 1.4% before recovering 1.3% over five days. Before that, January's Q4 result was far more painful: a 10.6% single-day decline that extended to a 14% loss over the following week. That January reaction appears to have been the catalyst for the short interest build-up that persisted through March. The partial unwind of that position this week is notable given the upcoming release. Consensus broadly expects another earnings decline — Zacks flagged this explicitly on April 23 — yet shorts are exiting, not adding.
With earnings due this morning, the interest sits on whether the Q1 print is incrementally better or worse than the January shock, and whether any guidance on tariff exposure or UK integration costs shifts the tone on the EBITDA margin trajectory.
See the live data behind this article on ORTEX.
Open GPI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
